Sarepta Therapeutics (SRPT) Q4 2025 earnings summary

Executive summary

• Entered 2026 with strong financial footing, $954 million in cash/investments, and positive operating cash flow after decisive 2025 actions, including four marketed therapies and a robust product pipeline.

• ELEVIDYS launched in Japan in February 2026, triggering a $40 million milestone; over 1,200 patients treated globally.

• Positive three-year EMBARK study results for ELEVIDYS showed durable, statistically significant benefits in Duchenne muscular dystrophy.

• Corporate restructuring and refinancing of 2027 notes improved financial position and capital structure.

• Base business delivered full-year GAAP and non-GAAP operating profit and positive cash flow, excluding collaboration and restructuring charges.

Financial highlights

• 2025 total revenues reached $2.2 billion, up 16% year-over-year; net product revenue was $1.86 billion, with $965.6 million from PMOs and $898.7 million from ELEVIDYS.

• Q4 2025 product revenue was $369.6 million, with $259.2 million from PMO and $110.4 million from ELEVIDYS; Q4 revenues declined 42% year-over-year.

• GAAP operating loss for 2025 was $700 million; non-GAAP operating loss was $492 million, both impacted by $884 million Arrowhead collaboration costs and $42 million restructuring charges.

• Cost restructuring initiatives delivered $285 million in operating expense savings from initial 2025 guidance midpoint.

• Cash, cash equivalents, and investments totaled $954 million at year-end 2025.

Outlook and guidance

• 2026 net product revenue guidance: $1.2–$1.4 billion; collaboration and royalty revenue expected at $450–$550 million.

• Combined non-GAAP R&D and SG&A expenses projected at $800–$900 million; GAAP at $925–$1,075 million.

• Expectation to remain cash flow positive and profitable on a non-GAAP basis in 2026.

• Q1 2026 revenue expected to be flat to down 15% sequentially due to long cycle times and delayed infusions.

• Commercial initiatives anticipated to impact demand in 2H 2026 and beyond.